Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
Portfolio Pulse from
Biofrontera Inc. has completed patient enrollment for its Phase 3 study of Ameluz® gel for treating actinic keratoses on the extremities, neck, and trunk. This development could expand treatment options for this common skin condition.
March 18, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biofrontera Inc. has completed patient enrollment for its Phase 3 study of Ameluz® gel, which could lead to expanded treatment options for actinic keratoses, potentially boosting the company's market position.
The completion of patient enrollment in a Phase 3 trial is a significant milestone in drug development. If successful, the trial could lead to regulatory approval for Ameluz® gel for a broader range of actinic keratoses, potentially increasing Biofrontera's market share and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100